Literature DB >> 15060444

Which nucleoside and nucleotide backbone combinations select for the K65R mutation in HIV-1 reverse transcriptase.

Alan Winston1, Anton Pozniak, Sundhiya Mandalia, Brian Gazzard, Deenan Pillay, Mark Nelson.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15060444     DOI： 10.1097/00002030-200404090-00014

Source DB:  PubMed          Journal:  AIDS        ISSN： 0269-9370            Impact factor:   4.177


× No keyword cloud information.
  7 in total

Review 1.  Changing patterns in the selection of viral mutations among patients receiving nucleoside and nucleotide drug combinations directed against human immunodeficiency virus type 1 reverse transcriptase.

Authors:  Mark A Wainberg; Bluma G Brenner; Dan Turner
Journal:  Antimicrob Agents Chemother       Date:  2005-05       Impact factor: 5.191

2.  Intracellular nucleotide levels during coadministration of tenofovir disoproxil fumarate and didanosine in HIV-1-infected patients.

Authors:  Trevor Hawkins; Wenoah Veikley; Lucie Durand-Gasselin; Darius Babusis; Y Sunila Reddy; John F Flaherty; Adrian S Ray
Journal:  Antimicrob Agents Chemother       Date:  2011-01-31       Impact factor: 5.191

3.  In vitro activity of structurally diverse nucleoside analogs against human immunodeficiency virus type 1 with the K65R mutation in reverse transcriptase.

Authors:  Urvi M Parikh; Dianna L Koontz; Chung K Chu; Raymond F Schinazi; John W Mellors
Journal:  Antimicrob Agents Chemother       Date:  2005-03       Impact factor: 5.191

4.  The K65R mutation in human immunodeficiency virus type 1 reverse transcriptase exhibits bidirectional phenotypic antagonism with thymidine analog mutations.

Authors:  Urvi M Parikh; Lee Bacheler; Dianna Koontz; John W Mellors
Journal:  J Virol       Date:  2006-05       Impact factor: 5.103

Review 5.  Tenofovir disoproxil fumarate: a review of its use in the management of HIV infection.

Authors:  Katherine A Lyseng-Williamson; Neil A Reynolds; Greg L Plosker
Journal:  Drugs       Date:  2005       Impact factor: 9.546

Review 6.  Abacavir plus lamivudine: a review of their combined use in the management of HIV infection.

Authors:  Toni M Dando; Lesley J Scott
Journal:  Drugs       Date:  2005       Impact factor: 9.546

7.  Clinical and genotypic findings in HIV-infected patients with the K65R mutation failing first-line antiretroviral therapy in Nigeria.

Authors:  Claudia A Hawkins; Beth Chaplin; John Idoko; Ernest Ekong; Isaac Adewole; Wadzani Gashau; Robert L Murphy; Phyllis Kanki
Journal:  J Acquir Immune Defic Syndr       Date:  2009-10-01       Impact factor: 3.731
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.